letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...345678910111213...99100»
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  A Modified Technique for Inducing Polycystic Ovary Syndrome in Mice. (Pubmed Central) -  Jul 22, 2024   
    Letrozole-induced mouse models replicate the metabolic and reproductive phenotypes of patients with PCOS...The materials and equipment used in this study are readily available to most laboratories, requiring no special customization. Collectively, this article provides a unique, easy-to-perform method for inducing PCOS in mice.
  • ||||||||||  letrozole / Generic mfg.
    Retrospective data, Review, Journal:  Efficacy of letrozole for the treatment of tubal ectopic pregnancy: A meta-analysis. (Pubmed Central) -  Jul 18, 2024   
    Although this meta-analysis suggests efficacy and low hazard of the drug and encourages its application, the data available today remain extremely sparse, which weakens any claims that can be made, and is not sufficient to assert that letrozole is safe and effective in the treatment of EPs. There is an absolute need for randomized studies with accurate patient selection, fixed doses, large sample sizes, and reporting of short- and long-term side effects to refute or confirm this assumption.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    MULTIPLE ILEAL AND COLONIC STENOSES: IS IT ALWAYS CROHN (Poster Stage 2) -  Jul 18, 2024 - Abstract #UEGW2024UEGW_1936;    
    It could be the first manifestation of the tumor and may mimic symptoms and imaging appearance of CD, resulting in challenging diagnosis. False-negative histology at endoscopic specimens warrants consideration of alternative diagnoses, and histological diagnosis sometimes is only possible with surgery.
  • ||||||||||  letrozole / Generic mfg.
    SMALL BOWEL OBSTRUCTION DUE TO PERITONEAL METASTASIS FROM BREAST CARCINOMA - CASE REPORT (Science Lounge) -  Jul 18, 2024 - Abstract #UEGW2024UEGW_933;    
    False-negative histology at endoscopic specimens warrants consideration of alternative diagnoses, and histological diagnosis sometimes is only possible with surgery. Clinical Case Summary: Peritoneal dissemination from cancer of extraperitoneal origin is rare1,2.We report a patient who presented with symptoms and signs of small bowel obstruction(SBO)due to breast metastasis in the omentum.A 73-year-old female complained of irregular bowel movement,flatulence and abdominal pain.Her past medical history was significant for breast examination 2 years earlier with suspicion of tumor,but without confirmation of any tumor on control breast ultrasound and radiography.After upper and lower endoscopy showed no significant pathology, her initial presentation was characterized as irritable colon syndrome.After worsening of the symptoms with nausea and vomiting and weight loss for the period of one year, the patient was referred to our Clinic.Initial magnetic resonance enterography showed slight dilatation of small bowel loops,without other pathology.She was sent to the surgeon who excluded indication for surgery.Three months later,the patient came back to the GI with same symptoms of suboclusion.Repeat MRE showed small bowel loops dilatation(40 mm),slight ascites and again no other pathology was detected.The patient had undergone explorative laparotomy when marked dilatation of small bowel loops was noted as well as thickening and multiple secondary lesions of the omentum.Ex-tempore biopsy of the omentum confirmed malignancy.The patient was treated for adhesion-induced ileus and a biopsy of the omentum was performed.Histopathology and immunohistochemistry were consistent with peritoneal dissemination from the breast cancer.The surgery was uneventful, and the patient was started with hormonal therapy(letrozole).At the latest follow up 6 months after the surgery, no oclusion episodes were reported.Diagnosis of peritoneal metastasis is challenging and may require surgical exploration as it was shown in our case.Physicians should be aware of the possibility of SBO caused by metastasis from the breast cancer, particularly in patients with a related history of cancer.
  • ||||||||||  Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    Journal, HEOR, Cost-effectiveness, Cost effectiveness:  Cost-Effectiveness of Adjuvant Abemaciclib and Ribociclib in High-Risk Hormone Receptor-Positive Early Breast Cancer: An Indian Perspective. (Pubmed Central) -  Jul 18, 2024   
    Clinical Case Summary: Peritoneal dissemination from cancer of extraperitoneal origin is rare1,2.We report a patient who presented with symptoms and signs of small bowel obstruction(SBO)due to breast metastasis in the omentum.A 73-year-old female complained of irregular bowel movement,flatulence and abdominal pain.Her past medical history was significant for breast examination 2 years earlier with suspicion of tumor,but without confirmation of any tumor on control breast ultrasound and radiography.After upper and lower endoscopy showed no significant pathology, her initial presentation was characterized as irritable colon syndrome.After worsening of the symptoms with nausea and vomiting and weight loss for the period of one year, the patient was referred to our Clinic.Initial magnetic resonance enterography showed slight dilatation of small bowel loops,without other pathology.She was sent to the surgeon who excluded indication for surgery.Three months later,the patient came back to the GI with same symptoms of suboclusion.Repeat MRE showed small bowel loops dilatation(40 mm),slight ascites and again no other pathology was detected.The patient had undergone explorative laparotomy when marked dilatation of small bowel loops was noted as well as thickening and multiple secondary lesions of the omentum.Ex-tempore biopsy of the omentum confirmed malignancy.The patient was treated for adhesion-induced ileus and a biopsy of the omentum was performed.Histopathology and immunohistochemistry were consistent with peritoneal dissemination from the breast cancer.The surgery was uneventful, and the patient was started with hormonal therapy(letrozole).At the latest follow up 6 months after the surgery, no oclusion episodes were reported.Diagnosis of peritoneal metastasis is challenging and may require surgical exploration as it was shown in our case.Physicians should be aware of the possibility of SBO caused by metastasis from the breast cancer, particularly in patients with a related history of cancer. The combination of adjuvant abemaciclib or ribociclib with letrozole is not cost-effective for HR+/HER2- EBC in India in either the BC or WC scenario.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov) -  Jul 17, 2024   
    P2,  N=19, Completed, 
    The present report provides a new treatment strategy by incorporating CDK4/6 inhibitors in the therapeutic armamentarium of breast NECs. Active, not recruiting --> Completed
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Journal:  Synergistic Enhancement of Antitumor Effects by Combining Abemaciclib with Desipramine. (Pubmed Central) -  Jul 13, 2024   
    The combination treatment significantly reduced tumor size compared with control or single treatment without causing apparent toxicity to normal tissues. Although additional in vivo studies are necessary, this study suggests that the combination therapy of abemaciclib and desipramine may represent a novel therapeutic approach for treating solid tumors.
  • ||||||||||  letrozole / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer (clinicaltrials.gov) -  Jul 9, 2024   
    P2,  N=21, Completed, 
    This may shorten time to ovulation and pregnancy. Recruiting --> Completed | N=50 --> 21 | Trial completion date: Jun 2025 --> Sep 2023 | Trial primary completion date: Jun 2024 --> Sep 2023
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Hyperandrogenemia elevates expression of apelin and apelin receptor protein in the mice pituitary. (Pubmed Central) -  Jul 8, 2024   
    Thus, we have investigated the expression and localization of apelin and its receptor, APJ, in the letrozole-induced hyperandrogenised pituitary of female mice...Thus, apelin could be one of the factors for deregulated gonadotropin secretion in hyperandrogenised conditions. However, more research is needed to fully understand the complex interactions between apelin and androgen regarding gonadotropin secretion in hyperandrogenised conditions.
  • ||||||||||  Vegzelma (bevacizumab-adcd) / Celltrion, Avastin (bevacizumab) / Roche, Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz
    Trial completion date:  CALGB-40503: Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer (clinicaltrials.gov) -  Jun 25, 2024   
    P3,  N=394, Active, not recruiting, 
    When the identification of high-risk pT1a pN0 HER2-positive breast cancer is possible, postoperative anti-HER2 therapy plus chemotherapy would be effective in decreasing the rate of recurrence. Trial completion date: Jul 2024 --> May 2025
  • ||||||||||  letrozole / Generic mfg.
    Clinical, Review, Journal:  Trends in acupuncture for infertility: a scoping review with bibliometric and visual analysis. (Pubmed Central) -  Jun 19, 2024   
    Current research highlights on acupuncture for infertility resulting in natural conception focused on female infertility caused by polycystic ovary syndrome, ovulation disorder, and LUFS, while studies on male infertility and female infertility caused by blockage in the fallopian tube, thin endometrium, and other factors were insufficient. Well-designed confirmatory clinical studies are still needed as the research hypotheses of most studies were unclear.
  • ||||||||||  letrozole / Generic mfg., exemestane / Generic mfg.
    Journal:  Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane. (Pubmed Central) -  Jun 17, 2024   
    To the best of our knowledge, we present here for the first time a comprehensive and direct head-to-head, intra-patient-cross-over comparison of the aromatase inhibitor letrozole and the aromatase inactivator exemestane concerning their ability to suppress serum estrogen levels in vivo. All in all, our results clearly demonstrate that letrozole therapy results in a more profound suppression of serum E1 and E2 levels compared to exemestane.
  • ||||||||||  letrozole / Generic mfg., epirubicin / Generic mfg.
    Journal:  Gastric metastasis and peritoneal carcinosis revealing primary breast cancer: an unusual presentation. (Pubmed Central) -  Jun 17, 2024   
    Further investigations led to bilateral invasive lobular breast carcinoma diagnosis. Epirubicin cycophosphamide was prescribed after progression under letrozole ribocilib therapy.This case aims to raise awareness among clinicians about the importance of ruling out breast cancer in patients with peritoneal carcinosis and paying attention to digestive symptoms in breast cancer patients with careful gastric endoscopic examination to avoid misdiagnosis.
  • ||||||||||  letrozole / Generic mfg.
    Observational data, Retrospective data, Journal:  Letrozole and ovarian hyperstimulation syndrome: Retrospective cross-sectional study. (Pubmed Central) -  Jun 13, 2024   
    The parameters of OHSS severity, hospitalization rates, and the need for albumin prescription showed no significant differences between the groups. Recent study indicates that incorporating letrozole into the treatment of GnRH antagonists and cabergoline does not reduce the OHSS severity.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Trial completion date, Trial primary completion date:  Roll-over Study to Allow Continued Access to Ribociclib (clinicaltrials.gov) -  Jun 12, 2024   
    P4,  N=137, Recruiting, 
    Recent study indicates that incorporating letrozole into the treatment of GnRH antagonists and cabergoline does not reduce the OHSS severity. Trial completion date: Sep 2029 --> Mar 2030 | Trial primary completion date: Aug 2029 --> Feb 2030